-
Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer
Recruiting
More
The purpose of this study is to (1) describe patient and clinician engagement in web-based
symptom self-monitoring, (2) identify differences in symptom management between intervention
and usual care groups, and (3) identify potential outcomes of real-time symptom tracking and
management.
With the assistance of the study coordinator, participants randomized to the intervention
will create an account with Noona. Patients will be instructed to log symptoms as often as
relevant using their own personal devices. Patients will also be prompted once per week for
24 weeks to log any recent symptoms. These participants will be sent a Symptom Questionnaire
(SQ) via the Noona tool that summarizes their symptoms and distress one week prior to each
oncology clinic visit. Symptoms designated as clinically severe either during regular symptom
logging or via the SQ will trigger a prompt to contact the clinical team for immediate
follow-up.
Lead Sponsor
Stanford Investigators
View full details
-
Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia
Recruiting
More
AML is the most common leukemia diagnosed in adults. In spite of recent low-intensity
therapies that have improved outcomes for older AML patients, AML remains associated with
poor prognosis as well as high symptom burden. While the benefits of early palliative care as
well as electronic PROs have been well-described in the oncology population, neither have
been well-studied in the AML population, and have never been studied in combination. We
propose a prospective, single-center, single-arm trial to evaluate the feasibility of a
virtually-mediated supportive care model utilizing both electronic PROs and palliative care
for patients with AML being treated with low-intensity therapy.
AIM1: is to evaluate and describe the feasibility of implementing early specialty palliative
care referrals carried out via telehealth/video-based modalities in combination with digital
symptom monitoring for patients recently diagnosed with acute myeloid leukemia (AML) and
starting low intensity induction therapy.
AIM2: study the differences in health-related quality-of-life (HRQoL) metrics using
patient-reported outcomes (PROs) in patients recently diagnosed with AML and starting low
intensity induction therapy who receive early referral to telehealth/video-based palliative
care visits compared to standard care.
AIM3: to explore the patient experience of patients with AML on low-intensity therapy,
capture rates of advance care planning, hospice utilization, and hospital utilization.
Lead Sponsor
Stanford Investigators
View full details
-
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. This may be an
effective treatment for extensive stage small cell lung cancer.
PURPOSE: This randomized phase II trial is comparing how well radiation therapy to the brain
works when given with or without radiation therapy to other areas of the body in treating
patients with extensive stage small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
Recruiting
More
This first time in human study is intended for men and women at least 18 years of age who
have advanced lung cancer which has grown or returned after being treated. In particular, it
is a study for subjects who have a blood test positive for HLA-A*02:01 and/or HLA-A*02:06 and
a tumor test positive for MAGE A10 protein expression (protein or gene). This trial is a dose
escalation trial that will evaluate 3 doses of transduced cells administered after a
lymphodepleting chemotherapy regimen using a 3+3 dose escalation design .The study will take
the subject's T cells, which are a natural type of immune cell in the blood, and send them to
a laboratory to be modified. The changed T cells used in this study will be the subject's own
T cells that have been genetically changed with the aim of attacking and destroying cancer
cells.
When the MAGE A10ᶜ⁷⁹⁶T cells are available, subjects will receive lymphodepleting
chemotherapy with cyclophosphamide and fludarabine, followed by the T cell infusion. The
purpose of this study is to test the safety of genetically changed T cells and find out what
effects, if any, they have in subjects with lung cancer. The study will evaluate three
different cell dose levels in order to find out the target cell dose. Once the target cell
dose is determined, additional subjects will be enrolled to further test the safety and
effects at this cell dose.
Subjects will be seen frequently by the Study Physician right after receiving their T cells
back and up to first 6 months. After that, subjects will be seen every three months. Subjects
will be seen every 6 months by their Study Physician for the first 5 years after the T cell
infusion. If the T cells are found in the blood at five years, then the subjects will
continue to be seen once a year until the T cells are no longer found in the blood for a
maximum of 15 years. If the T cells are no longer found in the blood at 5 years, then the
subject will be contacted by the Study Physician for the next 10 years. Subjects who have a
confirmed response or clinical benefit ≥4 weeks after the first T-cell infusion and whose
tumor continues to express the appropriate antigen target may be eligible for a second
infusion. All subjects, completing or withdrawing from the Interventional Phase of the study,
will enter a 15-year long-term follow-up phase for observation of delayed adverse events. All
subjects will continue to be followed for overall survival during the long-term follow-up
phase.
Stanford Investigators
View full details
-
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer
Not Recruiting
More
AC0010MA is a new, irreversible, Epidermal Growth Factor Receptor (EGFR) mutation selective
Tyrosine Kinase Inhibitor. Aim at local advanced or metastatic non-small cell lung cancer
patients with EGFR mutation or T790M drug-resistant mutation. The molecular mechanism: by
irreversible combining the EGFR-RTKs ATP binding site of cell, selectively suppress the
activities of EGFR tyrosine kinase phosphorylation, block the signal transduction pathway of
EGFR and inhibit the function of ras/raf/MAPK downstream, thus block the tumor cell growth by
EGFR induction, and promotes apoptosis. AC0010MA Maleate Capsules has three characters: 1.
Irreversible binding to EGFR; 2. Effectively suppresses the tumor cell with EGFR mutant while
has no suppression to EGFR wild-type cell; 3. Efficient suppress the tumor cell with EGFR
T790M drug-resistant mutation.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
Not Recruiting
More
This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab
(MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC.
Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab
(MPDL3280A) on Day 1 of 21-day cycles until disease progression.
Eligible participants will be categorized in to three groups as follows:
1. Participants with no prior chemotherapy for advanced disease;
2. Participants who progress during or following a prior-platinum based chemotherapy
regimen for advanced disease (2L+participants);
3. Participants who are 2L+ and previously treated for brain metastases.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 650-736-4112.
Stanford Investigators
View full details
-
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Not Recruiting
More
This phase I trial studies the side effects and best dose of necitumumab when given together
with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is
stage IV or has come back after a period of improvement (recurrent) and who have progressed
on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such
as necitumumab, may induce changes in body's immune system and may interfere with the ability
of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be a
better treatment for EGFR-mutant non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sukhmani K. Padda, 650-498-7061.
Stanford Investigators
View full details
-
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Not Recruiting
More
In this research study erlotinib will be given to eligible participants whose lung cancer has
been removed by surgery. Eligible patients have adenocarcinoma, a type of non-small lung
cancer, and must have 1 or more of the following characteristics: be female, be of Asian or
Pacific Rim descent and/or be a never smoker. The potential participant's tumor will be
examined for Epidermal growth factor (EGFR) mutations. EGFR is a protein that is
overexpressed in most non-small cell lung cancers. Some EGFR has been found to have specific
mutations and the participant must have one of these mutations in his tumor.
Erlotinib blocks this protein and may control tumor growth and increase survival. Previous
research has shown that erlotinib is most effective for people who have these specific
mutations in the EGFR.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lei Shura, 650-723-2312.
Stanford Investigators
View full details
-
Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor
Recruiting
More
Approximately 22% of term pregnancies are induced. Misoprostol, a prostaglandin E1 analogue,
is a widely accepted induction agent, that has been proven safe and effective for induction
of labor. It stimulates both cervical ripening and uterine contractions, thus making it an
ideal induction agent for unfavorable cervices. Research has examined the pharmacokinetics of
different administration routes and effects on uterine contractility, side effects, and
safety. Vaginal misoprostol has been shown to be superior over oral administration however
patients often prefer a more tolerable route. Buccal administration has already been shown to
be as effective as vaginal misoprostol for cervical ripening and induction in both first
trimester and second trimester abortions. There is minimal research comparing buccal versus
vaginal for third trimester induction of labor. The investigators study is a prospective,
double blinded, randomized control trial comparing vaginal misoprostol and buccal misoprostol
in equal dosages of 25 mcg. The investigators seek to answer the question whether buccal
misoprostol is as effective as vaginal misoprostol for third trimester induction of labor.
Stanford Investigators
View full details
-
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
Not Recruiting
More
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy
and radiation therapy. It is not yet known whether Manuka honey is more effective than
standard care in preventing pain.
PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it
works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation
therapy for lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Not Recruiting
More
This research study is a Phase II clinical trial, which tests the safety and effectiveness of
an investigational drug to learn whether the drug works in treating a specific cancer.
"Investigational" means that the drug is still being studied. It also means that the FDA has
not yet approved afatinib for use in patients.
In this research study the investigators are looking to see if taking afatinib after surgery
works better when taken over a short period of time, compared to a long period of time.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 650-736-4112.
Stanford Investigators
View full details
-
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Not Recruiting
More
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in
participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer
(NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3
weeks as long as participants are experiencing clinical benefit as assessed by the
investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration
attributed to disease progression.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 650-736-4112.
Stanford Investigators
View full details
-
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
Not Recruiting
More
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the
efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone
chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV
non-squamous non-small cell lung cancer. In Cohort 1, patients will be randomized to receive
4 cycles of bevacizumab (Avastin) 15 mg/kg iv, paclitaxel 200 mg/m2 iv, platinum
(cisplatin/carboplatin) iv plus either MetMab 15 mg/kg iv or placebo on Day 1 of each 21-day
cycle. In Cohort 2, patients will be randomized to receive pemetrexed 500 mg/m2 iv, platinum
(cisplatin/carboplatin) iv plus either MetMAb 15 mg/m2 iv or placebo on Day 1 of each 21-day
cycle. Patients who have not progressed after 4 cycles will be offered maintenance therapy
with their assigned treatment of bevacizumab plus either MetMAb or placebo (Cohort 1) or
pemetrexed plus either MetMAb or placebo (Cohort 2). Anticipated time on study treatment is
until disease progression or unacceptable toxicity occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie SanPedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Not Recruiting
More
This screening study is intended for men and women ≥ 18 to ≤ 75 years of age who have
advanced solid or hematologic malignancy. The study will assess a subject's human leukocyte
antigen (HLA) subtype and tumor antigen expression profile. Based on the results, it will be
determined if a subject is eligible to be considered for Adaptimmune sponsored clinical
trials testing the safety and efficacy of genetically changed T cells targeting specific
tumor antigens. No treatment intervention will occur as part of this screening study.
Upon enrollment, subjects will be required to provide a blood sample for HLA subtype
analysis. If the results of the analysis match the HLA-A subtypes noted in the inclusion
criteria and do not express the HLA subtypes that are exclusionary for the available
interventional clinical trial(s), then the subject will be required to provide either an
archival tumor specimen or fresh tumor tissue biopsy. The tumor specimen will be screened at
a central laboratory for the expression (protein or gene) of multiple antigens which may
include, but are not limited to MAGE-A4. Based upon the results of these diagnostic analyses,
if eligible, subjects will be referred to an appropriate available interventional clinical
trial(s) at the discretion of the Investigator.
Following screening, tumor samples will be retained by Adaptimmune for the purpose of
developing and validating in vitro diagnostic (IVD) assay(s) for antigen expression profiling
which is required for regulatory approval of a new therapeutic product indication.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Not Recruiting
More
This is a Phase III, global, multicenter, open-label, randomized study to compare the
efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A)
treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA
non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured
by disease-free survival (DFS) as assessed by the investigator and overall survival (OS).
Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will
be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Recruiting
More
This study is about a medicine called TAK-788, also known as mobocertinib, given to adults
with non-small cell lung cancer. The main aims of this study are to check if there are any
side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine
the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules
with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor
decide they should stop this treatment. Participants will take TAK-788 capsules with or
without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788
treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and
tolerability of TAK-788 treatment.
Stanford Investigators
View full details
-
Molecular Analysis of Thoracic Malignancies
Recruiting
More
A research study to learn about the biologic features of cancer development, growth, and
spread. We are studying components of blood, tumor tissue, normal tissue, and other fluids,
such as urine, cerebrospinal fluid, abdominal or chest fluid in patients with cancer. Our
analyses of blood, tissue, and/or fluids may lead to improved diagnosis and treatment of
cancer by the identification of markers that predict clinical outcome, markers that predict
response to specific therapies, and the identification of targets for new therapies.
Lead Sponsor
Stanford Investigators
View full details
-
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Recruiting
More
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA
non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in
a patient's tumor cells may help doctors select the best treatment for patients that have
certain genetic changes.
Stanford Investigators
View full details
-
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Not Recruiting
More
This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to
observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has
been completely removed by surgery (resected). Erlotinib hydrochloride may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Heather A. Wakelee, 650-724-3697.
Stanford Investigators
View full details
-
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer
Not Recruiting
More
This randomized phase II trial studies how well positron emission tomography (PET)/computed
tomography (CT)-guided radiation therapy works compared to standard radiation therapy in
treating patients with stage III non-small cell lung cancer. Radiation therapy uses
high-energy x-rays to kill tumor cells. Using imaging procedures, such as PET and CT scans,
to guide the radiation therapy, may help doctors deliver higher doses directly to the tumor
and cause less damage to healthy tissue.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 650-736-0798.
Stanford Investigators
View full details
-
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Not Recruiting
More
This screening and multi-sub-study randomized phase II/III trial will establish a method for
genomic screening of similar large cancer populations followed by assigning and accruing
simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer
trait (biomarker) will determine to which sub-study, within this protocol, a participant will
be assigned to compare new targeted cancer therapy, designed to block the growth and spread
of cancer, or combinations to standard of care therapy with the ultimate goal of being able
to approve new targeted therapies in this setting. In addition, the protocol includes a
?non-match? sub-study which will include all screened patients not eligible for any of the
biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of
care also with the goal of approval.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
More
This randomized phase III trial studies how well crizotinib works in treating patients with
stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation
in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make
it very active and important for tumor cell growth and progression. Crizotinib may stop the
growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an
effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Stanford Investigators
View full details
-
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Not Recruiting
More
This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in
combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid
tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Not Recruiting
More
The purpose of this study is to compare the anti-tumor efficacy of oral single-agent
rociletinib, as measured by investigator assessment of the PFS, with that of single-agent
cytotoxic chemotherapy in patients with EGFR-mutated, advanced/metastatic NSCLC after failure
of at least 1 previous EGFR-directed TKI and at least 1 line of platinum-containing doublet
chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 650-724-1388.
Stanford Investigators
View full details
-
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Not Recruiting
More
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment
of advanced cancers. The initial purpose of the study is to determine the largest amount of
X-396 that can be safely given to humans (the maximum tolerated dose). Once the recommended
Phase 2 dose has been determined, an expansion phase will assess the preliminary anti-tumor
activity of X-396 in ALK-positive non-small cell lung cancer. The study will also provide
early information on how the body handles the drug (pharmacokinetics) and on the efficacy of
X-396.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 650-724-1388.
Stanford Investigators
View full details
-
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Not Recruiting
More
The purpose of this study is to show that Nivolumab will improve progression free survival in
subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared
to chemotherapy
Stanford is currently not accepting patients for this trial.
For more information, please contact Smriti Rai, 650-723-0270.
Stanford Investigators
View full details
-
A Phase 1/2 Study to Evaluate MEDI4736
Not Recruiting
More
This is a multicenter, open-label, first-time-in-human study with a standard 3+3
dose-escalation phase in participants with advanced solid tumors followed by an expansion
phase in participants with advanced solid tumors. An exploration cohort has been added to
determine the safety using every 4 weeks (Q4W) dosing.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 650-724-1388.
Stanford Investigators
View full details
-
Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
Not Recruiting
More
This phase II trial studies how well pembrolizumab works in treating patients with
non-squamous non-small cell lung cancer which has spread to other places in the body.
Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells
to grow and spread.
Stanford is currently not accepting patients for this trial.
For more information, please contact Richard Quick, 650-723-2983.
Stanford Investigators
View full details
-
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Not Recruiting
More
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with
chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.
Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy
that delivers a high dose of radiation directly to the tumor may kill more tumor cells and
cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide,
paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading. It
is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib
with chemoradiation therapy in treating patients with non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Katie Brown, 650-723-1423.
Stanford Investigators
View full details
-
Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Not Recruiting
More
This study will evaluate the safety, preliminary efficacy, and pharmacokinetics (PK) of
momelotinib (MMB) and erlotinib, as well as define the maximum tolerated dose (MTD) of
momelotinib (MMB) combined with erlotinib in adults with epidermal growth factor receptor
(EGFR)-mutated, EGFR tyrosine kinase inhibitor (TKI) naive metastatic non-small cell lung
cancer (NSCLC). Participants will be sequentially enrolled to receive progressively
increasing doses of momelotinib (MMB) in combination with erlotinib. Escalation of
momelotinib (MMB) doses will proceed to the MTD, defined as the highest tested dose
associated with dose-limiting toxicities (DLT) during the first 28 days of combined erlotinib
and momelotinib (MMB) treatment. There will be four dose levels and each treatment cycle will
consist of 28 days.
Stanford is currently not accepting patients for this trial.
For more information, please contact Smriti Rai, 650-723-0270.
Stanford Investigators
View full details
-
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Not Recruiting
More
The purpose of this research study is to learn if adding hydroxychloroquine (HCQ) to
erlotinib helps treat non-small cell lung cancer (NSCLC). Another goal of this research study
is to learn more about NSCLC and how it may respond to study treatment. Erlotinib (Tarceva)
is a type of drug called a tyrosine kinase inhibitor (TKI). TKIs block a protein called the
epidermal growth factor receptor (EGFR). EGFR may control tumor growth and tumor cell
survival. However, although TKI drugs can work for some lung cancer patients for a period of
time, eventually the tumor finds a way to resist or counteract the TKI treatment and it
begins to grow again. Hydroxychloroquine (HCQ) is a drug approved by the FDA for treating
malaria, rheumatoid arthritis, and several other diseases. Laboratory research suggests that
when HCQ is given with a TKI, it may help delay or prevent TKI resistance from developing.
Stanford is currently not accepting patients for this trial.
For more information, please contact Zeina Babetty, 6507232983.
Stanford Investigators
View full details
-
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Not Recruiting
More
This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating
patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast
cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated
irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sophie Bertrand, 650-723-4467.
Stanford Investigators
View full details
-
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
Not Recruiting
More
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the
efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in
patients with incurable Stage IIIB or Stage IV squamous non-small cell lung cancer (NSCLC).
Patients will be randomized to receive either onartuzumab (MetMAb) 15 mg/kg iv or placebo on
Day 1 of each 21-day cycle in combination with 4 cycles of paclitaxel 200 mg/m2 iv and
platinum (carboplatin/cisplatin) iv on Day 1 of each 21-day cycle. Patients who have not
progressed after 4 cycles will continue with either onartuzumab (MetMAb) or placebo as
maintenance therapy until disease progression or unacceptable toxicity occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to evaluate progression-free survival among subjects with KRAS
mutation positive Non-Small Cell Lung Cancer (NSCLC) treated with erlotinib plus tivantinib
(ARQ 197) compared to single agent chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lei Shura, 650-723-2312.
Stanford Investigators
View full details
-
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Not Recruiting
More
A safety & efficacy clinical study of the investigational medicinal product BYM338 for the
treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
Not Recruiting
More
This phase I trial studies how well talactoferrin works in treating patients with relapsed or
refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer.
Biological therapies, such as talactoferrin, may stimulate the immune system in different
ways and stop tumor cells from growing
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Lead Sponsor
Stanford Investigators
View full details
-
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
Not Recruiting
More
This was a phase II, multi-center, open-label, five-arm study in which the efficacy and
safety of oral ceritinib treatment was assessed in patients with NSCLC metastatic to the
brain and/or to leptomeninges harboring a confirmed ALK rearrangement, using the FDA approved
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.) test and scoring algorithm
(including positivity criteria). If documentation of ALK rearrangement as described above was
not locally available, a test to confirm ALK rearrangement was performed by a Novartis
designated central laboratory. Patients waited for the central laboratory result of the ALK
rearrangement status before initiating treatment with ceritinib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Richard A Quick, 650-724-1388.
Stanford Investigators
View full details
-
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Not Recruiting
More
A single-arm, open-label, multicenter, phase II study. Treatment with LDK378 750 mg qd
continued until the patient experienced unacceptable toxicity that precluded further
treatment, discontinued treatment at the discretion of the investigator or patient, started a
new anti-cancer therapy and/or died. LDK378 could be continued beyond RECIST-defined
progressive disease (PD) as assessed by the investigator if, in the judgment of the
investigator, there was evidence of clinical benefit. In these patients tumor assessment
would continue as per the schedule of assessments until treatment with LDK378 was permanently
discontinued. Patients who discontinued the study medication in the absence of progression
continued to be followed for tumor assessment until the time of PD as assessed by the
investigator
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo , 650-724-1388.
Stanford Investigators
View full details
-
A ProspectiveTrial Using Video Images in Advance Care Planning in Hospitalized Seriously Ill Patients With Advanced Cancer
Not Recruiting
More
The purpose of this study is to compare the decision making of hospitalized subjects with
advanced cancer having a verbal discussion about CPR compared to subjects using a video.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ryan Oden, 6507255417.
Stanford Investigators
View full details
-
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Not Recruiting
More
Rociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI)
that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while
sparing wild-type (WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK)
and safety profile of oral rociletinib; to determine the maximum tolerated dose (MTD) and/or
recommended Phase 2 dose (RP2D) of oral rociletinib; to assess the safety and efficacy of
rociletinib in previously treated NSCLC patients known to have the T790M EGFR mutation.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro Salcedo, 650-724-1388.
Stanford Investigators
View full details
